Piper Sandler Reiterates Overweight on Abbott Laboratories, Raises Price Target to $118

Benzinga · 1d ago
Piper Sandler analyst Adam Maeder reiterates Abbott Laboratories (NYSE:ABT) with a Overweight and raises the price target from $115 to $118.